ZA953051B - 3,5-disubstituted tetrahydro uran-2-ones - Google Patents

3,5-disubstituted tetrahydro uran-2-ones

Info

Publication number
ZA953051B
ZA953051B ZA953051A ZA953051A ZA953051B ZA 953051 B ZA953051 B ZA 953051B ZA 953051 A ZA953051 A ZA 953051A ZA 953051 A ZA953051 A ZA 953051A ZA 953051 B ZA953051 B ZA 953051B
Authority
ZA
South Africa
Prior art keywords
opt
substd
alkylene
cooh
mono
Prior art date
Application number
ZA953051A
Other languages
English (en)
Inventor
Richard Goeschke
Peter Herold
Pascal Rigollier
Juergen Klaus Maibaum
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4204102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA953051(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of ZA953051B publication Critical patent/ZA953051B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/11—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton
    • C07C255/13—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
ZA953051A 1994-04-18 1995-04-13 3,5-disubstituted tetrahydro uran-2-ones ZA953051B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH116994 1994-04-18

Publications (1)

Publication Number Publication Date
ZA953051B true ZA953051B (en) 1995-10-18

Family

ID=4204102

Family Applications (3)

Application Number Title Priority Date Filing Date
ZA953051A ZA953051B (en) 1994-04-18 1995-04-13 3,5-disubstituted tetrahydro uran-2-ones
ZA953050A ZA953050B (en) 1994-04-18 1995-04-13 Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides
ZA953052A ZA953052B (en) 1994-04-18 1995-04-13 Alpha-aminoalkannic acids and reduction products

Family Applications After (2)

Application Number Title Priority Date Filing Date
ZA953050A ZA953050B (en) 1994-04-18 1995-04-13 Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides
ZA953052A ZA953052B (en) 1994-04-18 1995-04-13 Alpha-aminoalkannic acids and reduction products

Country Status (27)

Country Link
US (5) US5559111A (ko)
EP (1) EP0678503B1 (ko)
JP (1) JP3240322B2 (ko)
KR (1) KR100353779B1 (ko)
CN (2) CN1153759C (ko)
AT (1) ATE183997T1 (ko)
AU (1) AU699616B2 (ko)
BR (1) BR1100656A (ko)
CA (1) CA2147056C (ko)
CY (4) CY2208B1 (ko)
CZ (1) CZ287935B6 (ko)
DE (4) DE122007000071I2 (ko)
DK (1) DK0678503T3 (ko)
ES (1) ES2137478T3 (ko)
FI (1) FI118336B (ko)
GR (1) GR3031997T3 (ko)
HK (1) HK1070881A1 (ko)
HU (2) HU226860B1 (ko)
IL (1) IL113403A (ko)
LU (2) LU91373I2 (ko)
MY (1) MY119161A (ko)
NL (2) NL300296I2 (ko)
NO (4) NO310410B1 (ko)
NZ (1) NZ270936A (ko)
RU (1) RU95105970A (ko)
TW (2) TW366341B (ko)
ZA (3) ZA953051B (ko)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4408534A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Substituierte N-Ethyl-Glycinderivate zur Herstellung von PNA und PNA-/DNA-Hybriden
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0716077A1 (de) * 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
US6465650B1 (en) 1995-03-13 2002-10-15 Aventis Pharma Deutschland Gmbh Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids
DK1045839T3 (da) * 1997-12-16 2004-07-05 Warner Lambert Co Hidtil ukendte aminer som farmaceutiske midler
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) * 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6833460B2 (en) * 1999-06-18 2004-12-21 E. I. Du Pont De Nemours And Company Preparation and use of gamma-butyrolactones as cross-linking agents
US6423850B1 (en) 1999-06-18 2002-07-23 E.I. Du Pont De Nemours And Company Preparation and use of gamma-butyrolactones as cross-linking agents
EP1200390B1 (de) 1999-07-29 2008-08-27 Speedel Pharma AG Herstellung von n-substituierten 2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamiden
US6881868B2 (en) * 2000-07-03 2005-04-19 Speedel Pharma Ag Process for the preparation of (R)-2-alkyl-3-phenyl-1-propanols
DE60138099D1 (de) * 2000-07-05 2009-05-07 Speedel Pharma Ag Verfahren zur herstellung von substituierten octanoyl-amiden
CA2412452C (en) * 2000-07-25 2008-12-30 Speedel Pharma Ag Process for the preparation of substituted octanoyl amides
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DE60123911T2 (de) 2000-12-14 2007-05-31 Speedel Pharma Ag Verfahren zur Herstellung von Aryloctanoyl-amiden
JP3440082B2 (ja) 2001-02-19 2003-08-25 科学技術振興事業団 電気自動車用インホイールモーター
BR0209657B1 (pt) 2001-05-15 2014-10-21 Speedel Pharma Ag Processo para a preparação de ésteres de ácidos carboxílicos substituídos por hidrólise enzimática
WO2002100820A1 (en) * 2001-06-11 2002-12-19 Elan Pharmaceuticals, Inc. Substituted aminoalcohols useful in treatment of alzheimer's disease
WO2003035046A2 (en) * 2001-10-18 2003-05-01 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
US20050101638A1 (en) * 2002-11-08 2005-05-12 Webb Randy L. Combination of organic compounds
PL219032B1 (pl) * 2002-05-17 2015-03-31 Novartis Ag Kompozycja farmaceutyczna zawierająca alskiren, amlodypinę i hydrochlortiazyd, kombinacja zawierająca te składniki, zastosowanie wspomnianej kombinacji oraz zestaw handlowy zawierający wspomnianą kombinację
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
US20060154926A1 (en) * 2002-06-11 2006-07-13 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides
WO2003103652A1 (en) * 2002-06-11 2003-12-18 Elan Pharmaceuticals, Inc. METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES
JP4613130B2 (ja) * 2002-08-23 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ベンゾイミダゾールキノリノンおよびそれらの使用
US7049469B2 (en) 2002-10-24 2006-05-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing (R)-salbutamol
US7351738B2 (en) 2002-11-27 2008-04-01 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
BRPI0413838A (pt) * 2003-08-25 2006-10-24 Warner Lambert Co compostos de ariloxazolidinona antimicrobianos
EP1689702B1 (en) * 2003-11-26 2013-01-30 Novartis AG Organic compounds
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
PE20050596A1 (es) * 2003-12-19 2005-10-18 Novartis Ag Microemulsion que comprende un inhibidor renina
US20080234285A1 (en) * 2004-01-22 2008-09-25 David Louis Feldman Combination of Organic Compounds
ES2348016T3 (es) * 2004-01-23 2010-11-26 Novartis Ag Diamino alcoholoes y su uso como inhibidores de la renina.
DE602005025344D1 (de) * 2004-01-23 2011-01-27 Novartis Ag Aminoalkoholderivate und deren wirkung als renininhibitoren
PE20142101A1 (es) 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
US20070191487A1 (en) * 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
TW200605867A (en) 2004-03-17 2006-02-16 Novartis Ag Use of organic compounds
JP4927704B2 (ja) * 2004-03-19 2012-05-09 シュペーデル・エクスペリメンタ・アーゲー 有機化合物
PT1717226E (pt) * 2004-03-19 2009-04-03 Novartis Ag Derivados de 5-amino-4-hidroxi-8-(1h-indol-5-il)-octan amida 2,7-substituída como inibidores da renina para o tratamento da hipertensão
WO2005095876A1 (en) 2004-04-01 2005-10-13 Cucumber Limited Delivery and storage of goods
GB0419361D0 (en) 2004-08-31 2004-10-06 Novartis Ag Organic compounds
KR20130048281A (ko) 2004-10-08 2013-05-09 노파르티스 아게 확장기 기능장애 또는 확장기 심부전의 예방 또는 치료를 위한 레닌 억제제의 용도
TW200631929A (en) * 2004-12-10 2006-09-16 Speedel Experimenta Ag ω -phenyloctanamides
TW200633983A (en) * 2004-12-10 2006-10-01 Speedel Experimenta Ag 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-nonanamides
JP2008528691A (ja) * 2005-02-02 2008-07-31 ビテ ファーマシューティカルズ， インコーポレイテッド レニン阻害剤としての１−アシルアミノ−２−ヒドロキシ−３−アミノ−ω−アリールアルカン
CN101171230A (zh) * 2005-03-11 2008-04-30 斯皮德尔实验股份公司 用作肾素抑制剂的杂环取代的链烷酰胺
AR053826A1 (es) * 2005-03-11 2007-05-23 Speedel Experimenta Ag Compuestos organicos
WO2006097314A1 (de) * 2005-03-17 2006-09-21 Basf Aktiengesellschaft Verfahren zur herstellung von optisch aktiven 3-phenylpropionsäurederivaten und folgeprodukte davon
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
RU2470018C2 (ru) * 2005-07-11 2012-12-20 Новартис Аг Новые производные пирокатехина
US20070021413A1 (en) 2005-07-20 2007-01-25 Peter Herold Diamino alcohols as therapeutic compounds
EP1910272A4 (en) 2005-07-22 2010-08-04 Merck Frosst Canada Ltd INHIBITORS OF THE RENINE
EP1764098A1 (en) * 2005-09-17 2007-03-21 Speedel Experimenta AG Diaminoalcohols derivatives for the treatment of Alzheimer, malaria, HIV
CA2622082A1 (en) 2005-09-17 2007-03-22 Speedel Experimenta Ag 5-amino-4-hydroxy-7- (imidazo [1,2-a] pyridin-6- ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
PL1937248T3 (pl) * 2005-09-17 2010-11-30 Novartis Ag Amidy kwasów alkanowych podstawione nasyconymi grupami O-heterocyklicznymi
GB0519764D0 (en) * 2005-09-28 2005-11-09 Novartis Ag Organic compounds
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
US20080274171A1 (en) * 2005-10-18 2008-11-06 Nicoletta Almirante Renin Inhibitors Nitroderivatives
AU2006304836A1 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
GB2431648A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431649A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431645A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431646A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431642A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
DE102005052195A1 (de) * 2005-10-28 2007-05-03 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von chiralen Octensäurederivaten
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt
GB0605688D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
WO2007120523A2 (en) * 2006-03-31 2007-10-25 Vitae Pharmaceuticals, Inc. 6-(aminoalkyl)indazoles
US20100298328A1 (en) * 2006-03-31 2010-11-25 Vitae Pharmaceuticals, Inc 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes
CN101415413A (zh) * 2006-04-03 2009-04-22 诺瓦提斯公司 用于治疗高血压的肾素抑制剂
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
WO2007148775A1 (ja) * 2006-06-23 2007-12-27 Daiichi Sankyo Company, Limited 鎖状アミン化合物
AU2007262004B2 (en) * 2006-06-23 2011-07-07 Daiichi Sankyo Company, Limited Cyclic amine compound
KR101149274B1 (ko) 2006-07-20 2012-05-29 노파르티스 아게 Ｃετρ 억제제로서의 아미노-피페리딘 유도체
EP1911762A1 (en) 2006-10-04 2008-04-16 Speedel Experimenta AG Amino alcohols and their use as renin inhibitors
CN101594857B (zh) * 2006-11-07 2012-10-31 诺瓦提斯公司 阿利吉仑半富马酸盐的晶形
KR20090081010A (ko) * 2006-11-09 2009-07-27 노파르티스 아게 알리스키렌의 오로트산과의 염
EP1938812A1 (en) * 2006-12-22 2008-07-02 Speedel Pharma AG Pharmaceutical composition using aliskiren and avosentan
EP1958666A1 (en) 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
WO2008113835A1 (en) * 2007-03-21 2008-09-25 Novartis Ag Process for preparing (r or s)-5-{1-azido-3-[6-methoxy-5-(3-methoxy-propoxy)-pyridin-3-ylmethyl]-4-methyl-pentyl}-3-alkyl-dihydro-furan-2-one
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
CN101679213A (zh) * 2007-04-03 2010-03-24 诺瓦提斯公司 新方法
WO2009007461A1 (en) * 2007-07-11 2009-01-15 Dsm Ip Assets B.V. Preparation of a saturated aldehyde
US20090076062A1 (en) * 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
US20090082458A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched aliskiren
CL2008002828A1 (es) 2007-09-28 2009-05-15 Novartis Ag Tableta oral que comprende una cantidad mayor de 38% de alisquireno o una de sus sales y fosfato acido de calcio como relleno.
DE102007049039A1 (de) 2007-10-11 2009-04-16 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
PE20090982A1 (es) 2007-11-05 2009-08-13 Novartis Ag Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
EP2220031A1 (en) 2007-11-13 2010-08-25 Teva Pharmaceutical Industries Ltd. Polymorphic forms of aliskiren hemifumarate and process for preparation thereof
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
CA2707651A1 (en) 2007-12-03 2009-06-11 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
EP2075244A1 (en) 2007-12-24 2009-07-01 DSMIP Assets B.V. New route to building block for making renin inhibitors
US20110111021A1 (en) 2008-02-22 2011-05-12 Hanall Biopharma Co., Ltd. Pharmaceutical preparation
WO2009125981A2 (ko) 2008-04-10 2009-10-15 한올제약주식회사 약제학적 제제
US20100029774A1 (en) * 2008-05-23 2010-02-04 Nina Finkelstein Aliskiren monofumarate and processes for preparation thereof
US20120095264A1 (en) * 2008-06-06 2012-04-19 Teva Pharmaceutical Industries Ltd. Solid states of aliskiren free base
EP2143425A1 (de) 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
WO2010024772A1 (en) * 2008-08-29 2010-03-04 Medivir Ab Aspartyl protease inhibitors
EP2163245A1 (en) 2008-09-10 2010-03-17 Novartis Ag Renin inhibitors for the treatment of psoriasis
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
TWI468191B (zh) 2009-01-28 2015-01-11 Novartis Ag 有機化合物之調配物
US8148576B2 (en) * 2009-02-05 2012-04-03 Teva Pharmaceutical Industries Ltd. Solid state forms of aliskiren compounds
EA201190091A1 (ru) 2009-02-05 2012-01-30 Крка, Товарна Здравил, Д. Д., Ново Место Активируемый влагой способ грануляции
WO2010107971A1 (en) 2009-03-20 2010-09-23 Novartis Ag Galenical formulations of a fixed dose combination of valsartan and aliskiren
CN102361633A (zh) 2009-03-20 2012-02-22 诺瓦提斯公司 包含阿利吉仑的药物组合物
JP2012522746A (ja) 2009-04-01 2012-09-27 レツク・フアーマシユーテイカルズ・デー・デー 活性メチレン基のジメチル化の方法
WO2011019789A1 (en) 2009-08-11 2011-02-17 Novartis Ag The ring opening of lactones and lactams
WO2011028919A2 (en) 2009-09-03 2011-03-10 Teva Pharmaceutical Industries Ltd. Solid forms of aliskiren hemifumarate and processes for preparation thereof
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
WO2011048523A1 (en) * 2009-10-21 2011-04-28 CarboDesign LLC Process for the manufacture of enantiomerically pure aryloctanoic acids as aliskiren
WO2011051853A1 (en) * 2009-10-29 2011-05-05 CarboDesign LLC Manufacturing process for preparing enaniomerically pure 8- aryloctanoic acid derivatives such as aliskiren
CN102822152A (zh) * 2009-11-09 2012-12-12 诺瓦德克斯制药股份有限公司 新颖的1,3-噁唑烷化合物及其作为肾素抑制剂的用途
US20110113995A1 (en) * 2009-11-13 2011-05-19 Lindsay Corporation Method and apparatus for planting and irrigation
US20110137047A1 (en) * 2009-12-07 2011-06-09 CarboDesign LLC Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
CN101774986B (zh) 2010-01-06 2012-03-28 浙江天宇药业股份有限公司 一种制备阿利克伦及其中间体的方法
CN102140068B (zh) * 2010-01-30 2015-03-11 浙江华海药业股份有限公司 阿利吉仑中间体3-氨基-2,2-二甲基丙酰胺的制备方法
WO2011098258A1 (en) * 2010-02-10 2011-08-18 Ratiopharm Gmbh Salts of aliskiren
TW201136582A (en) 2010-03-16 2011-11-01 Novartis Ag Improved pharmaceutical compositions of aliskiren and methods of delivery
TR201002256A1 (tr) * 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
EP2382967A1 (de) 2010-04-21 2011-11-02 ratiopharm GmbH Aliskiren in Form einer festen Dispersion
US20110268797A1 (en) 2010-04-30 2011-11-03 Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi Multicoated aliskiren formulations
CN102241650B (zh) * 2010-05-14 2014-05-07 浙江九洲药业股份有限公司 用于制备阿立克仑的中间体化合物及相关制备方法
IT1400961B1 (it) * 2010-06-04 2013-07-05 Chemo Iberica Sa Processo per la produzione di aliskiren
IT1402925B1 (it) * 2010-12-10 2013-09-27 Chemo Iberica Sa Processo per la produzione di aliskiren
TW201202178A (en) 2010-06-04 2012-01-16 Chemo Iberica Sa Process for producing Aliskiren
CN101913998A (zh) * 2010-07-06 2010-12-15 上海朴颐化学科技有限公司 4-溴-2-(3-甲氧基丙氧基)-苯甲醚的制备方法
WO2012034065A1 (en) 2010-09-09 2012-03-15 Teva Pharmaceutical Industries Ltd. Aliskiren intermediates and a process for analyzing the purity of aliskiren
EP2630118B1 (en) 2010-10-19 2014-11-05 Mylan Laboratories Limited Synthesis of aliskiren
CN102001920B (zh) 2010-11-09 2013-05-15 常州制药厂有限公司 一种药物中间体的制备方法
CN102161627A (zh) * 2011-02-24 2011-08-24 中国药科大学 ω-(N取代-氨基烷基)辛酰胺
EP2551260A1 (en) 2011-07-28 2013-01-30 Chemo Ibérica, S.A. Chemical process for opening ring compounds
CN102942477B (zh) * 2011-08-14 2015-12-02 浙江华海药业股份有限公司 辛烯酸衍生物及其制备方法
CN102351734B (zh) * 2011-09-05 2014-02-26 浙江普洛医药科技有限公司 一种阿利克仑的制备方法
WO2013045505A1 (en) 2011-09-28 2013-04-04 Novartis Ag Biomarkers for raas combination therapy
US8703976B2 (en) * 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren
WO2013061224A1 (en) 2011-10-25 2013-05-02 Jubilant Life Sciences Limited Process for the preparation of aliskiren
WO2013118138A1 (en) 2011-12-13 2013-08-15 Laboratories Ltd Mylan Novel process for the preparation of renin inhibitors
CN103172533B (zh) * 2011-12-20 2016-05-04 博瑞生物医药（苏州）股份有限公司 一种阿利克仑半富马酸盐的新晶型及其制备方法和用途
CN103204834A (zh) * 2012-01-11 2013-07-17 南京欧信医药技术有限公司 阿利克伦中间体及其制备方法和应用
WO2013121443A1 (en) 2012-02-17 2013-08-22 Mylan Laboratories Ltd. An improved process for the preparation of aliskiren
WO2013124868A2 (en) 2012-02-21 2013-08-29 Mylan Laboratories Limited Solid form of aliskiren intermediate
ITMI20120354A1 (it) * 2012-03-07 2013-09-08 Friulchem Spa Processo per la produzione di aliskirene
WO2013144979A1 (en) 2012-03-28 2013-10-03 Maylan Laboratories Ltd Process for the preparation of aliskiren
CA2873869A1 (en) 2012-05-11 2013-11-14 Novartis Ag Dispensing device
WO2013171767A1 (en) 2012-05-18 2013-11-21 Mylan Laboratories Limited An improved process for the preparation of aliskiren
EP2810644A1 (en) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
WO2014207206A1 (en) * 2013-06-27 2014-12-31 Dpx Holdings B.V. Preparation of grignard reagents using a fluidized bed
CN117542473A (zh) 2018-06-14 2024-02-09 阿斯利康(英国)有限公司 用血管紧张素ii受体阻滞剂医药组合物治疗高血压的方法
CN112679448B (zh) * 2020-12-31 2022-08-19 苏州昊帆生物股份有限公司 N-(2-氨基乙基)吗啉的制备方法
CN115340472B (zh) * 2022-09-19 2024-05-07 合肥工业大学 一种谷氨酸衍生物及其合成方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337207A (en) * 1980-09-04 1982-06-29 Regents Of The University Of California Biologically active catecholamine derivatives
US4729985A (en) * 1985-08-09 1988-03-08 Pfizer Inc. Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
JPH02124884A (ja) * 1988-07-08 1990-05-14 Zhongguo Yixuekexueyuan Yaowo Yanjiusuo Ｎ―置換アミド誘導体
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities

Also Published As

Publication number Publication date
NO951441L (no) 1995-10-19
CZ97695A3 (en) 1995-11-15
CY2009006I2 (el) 2010-07-28
BR1100656A (pt) 2000-06-06
FI951771A (fi) 1995-10-19
NO951441D0 (no) 1995-04-12
DE122007000071I2 (de) 2009-01-02
US5646143A (en) 1997-07-08
NO2007011I1 (no) 2007-12-11
GR3031997T3 (en) 2000-03-31
CA2147056C (en) 2005-10-25
HU9501076D0 (en) 1995-06-28
LU91373I2 (fr) 2007-12-31
US5559111A (en) 1996-09-24
RU95105970A (ru) 1997-01-10
HUT74074A (en) 1996-10-28
KR100353779B1 (ko) 2003-01-08
DK0678503T3 (da) 2000-03-20
FI951771A0 (fi) 1995-04-12
CZ287935B6 (cs) 2001-03-14
DE122007000071I1 (de) 2008-01-31
IL113403A0 (en) 1995-07-31
CN1266118C (zh) 2006-07-26
NL300296I2 (nl) 2008-02-01
AU699616B2 (en) 1998-12-10
KR950032037A (ko) 1995-12-20
NO2009011I2 (no) 2010-11-22
NL300386I1 (nl) 2009-07-01
MY119161A (en) 2005-04-30
NO2009011I1 (no) 2009-06-02
NO2011020I1 (no) 2011-09-26
CN1550491A (zh) 2004-12-01
DE122011100052I1 (de) 2012-01-19
CY2011015I1 (el) 2014-04-09
NZ270936A (en) 1997-06-24
NO2007011I2 (ko) 2011-07-25
HK1070881A1 (en) 2005-06-30
FI118336B (fi) 2007-10-15
JP3240322B2 (ja) 2001-12-17
HU9501078D0 (en) 1995-06-28
HUT71701A (en) 1996-01-29
NO310410B1 (no) 2001-07-02
DE122009000020I1 (de) 2009-08-06
US5654445A (en) 1997-08-05
JPH0881430A (ja) 1996-03-26
CY2007027I2 (el) 2009-11-04
NL300296I1 (nl) 2007-12-03
EP0678503A1 (de) 1995-10-25
US5627182A (en) 1997-05-06
IL113403A (en) 2001-07-24
ATE183997T1 (de) 1999-09-15
CY2007027I1 (el) 2009-11-04
CN1153759C (zh) 2004-06-16
HU226860B1 (en) 2009-12-28
US5705658A (en) 1998-01-06
AU1642195A (en) 1995-10-26
CY2011015I2 (el) 2014-04-09
EP0678503B1 (de) 1999-09-01
TW366341B (en) 1999-08-11
CN1117960A (zh) 1996-03-06
TW402582B (en) 2000-08-21
ZA953052B (en) 1995-10-18
ZA953050B (en) 1995-11-08
CY2208B1 (en) 2002-11-08
DE59506707D1 (de) 1999-10-07
ES2137478T3 (es) 1999-12-16
CA2147056A1 (en) 1995-10-19
LU91564I2 (fr) 2009-07-06
CY2009006I1 (el) 2010-07-28

Similar Documents

Publication Publication Date Title
ZA953051B (en) 3,5-disubstituted tetrahydro uran-2-ones
AU1232388A (en) Process for improving the photochemical stability of dyeings on polyester fibre materials
AR017111A1 (es) Composiciones detergentes para el lavado de ropa con polimeros a base de aminas lineales para proporcionar beneficios en cuanto a aspecto exterior eintegridad a las telas lavadas con las mismas
EP0403062A3 (en) Tickened acidic liquid composition with amine fwa useful as a bleaching agent vehicle
EP0953563A4 (en) METHOD FOR PRODUCING DEPSIPEPTIDES AND INTERMEDIATE PRODUCTS THEREOF
ATE92479T1 (de) Neue 1,3-oxazine.
ATE140240T1 (de) Polymerverbindungen
ATE118214T1 (de) Salze von 3-(cis-2,6-dimethylpiperidino)- sydnonimin.
DK293889D0 (da) 2-amino-7-hydroxytetralinethere